Open Access

Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor‑treated patients with non‑small cell lung cancer exhibiting bone metastasis

  • Authors:
    • Xiaoxian Cui
    • Shaoli Li
    • Jincui Gu
    • Ziying Lin
    • Bipeng Lai
    • Lixia Huang
    • Jinlun Feng
    • Baomo Liu
    • Yanbin Zhou
  • View Affiliations

  • Published online on: September 16, 2019     https://doi.org/10.3892/ol.2019.10870
  • Pages: 5437-5447
  • Copyright: © Cui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Bisphosphonates (Bps) inhibit the maturation of osteoclasts and suppress the adhesion of cancer cells to the bone matrix. They are recommended as the standard treatment for tumors exhibiting bone metastasis (BM). However, whether Bps can improve the prognosis of patients with tyrosine kinase inhibitor (TKI)‑treated non‑small cell lung cancer (NSCLC) exhibiting BM remains unclear. A total of 129 patients with NSCLC initially diagnosed with BM at The First Affiliated Hospital of Sun Yat‑Sen University (Guangzhou, China) between January 2005 and December 2017 were analyzed in the present retrospective study. Median progression free survival (mPFS) time, median bone metastasis overall survival (mBM‑OS) time and bone‑associated progression‑free survival were analyzed. Among the 129 patients, patients treated with Bps experienced significantly prolonged PFS time [mPFS: 7.1 vs. 5.1 months; hazard ratio (HR), 0.51; confidence interval (CI), 0.30‑0.87; P=0.0114] in comparison with patients not treated with Bps. Of the 49 patients treated with frontline TKIs (EGFR TKIs or ALK TKI), 32 received Bps at the same time, while 17 patients received TKIs alone. The results revealed that mPFS time was significantly greater in the TKIs plus Bps group than in the TKIs alone group (mPFS: 11.2 vs. 6.9 months; HR, 0.13; CI, 0.05‑0.35; P<0.0001). Significantly prolonged BM‑OS time was also observed in the combination group in comparison with the TKIs alone group (mBM‑OS: 31 vs. 22 months; HR, 0.31; CI, 0.10‑0.96; P=0.0413). The present study demonstrated that among the patients who received TKIs (EGFR TKIs or ALK TKIs), those who also received Bps experienced significantly longer PFS time and tended to exhibit significantly improved BM‑OS time, which indicated that Bps should be added to the treatment regimen of patients with NSCLC exhibiting genetic mutations in the bone marrow who have been prescribed TKIs (EGFR TKIs or ALK TKIs).
View Figures
View References

Related Articles

Journal Cover

November-2019
Volume 18 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cui X, Li S, Gu J, Lin Z, Lai B, Huang L, Feng J, Liu B and Zhou Y: Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor‑treated patients with non‑small cell lung cancer exhibiting bone metastasis. Oncol Lett 18: 5437-5447, 2019
APA
Cui, X., Li, S., Gu, J., Lin, Z., Lai, B., Huang, L. ... Zhou, Y. (2019). Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor‑treated patients with non‑small cell lung cancer exhibiting bone metastasis. Oncology Letters, 18, 5437-5447. https://doi.org/10.3892/ol.2019.10870
MLA
Cui, X., Li, S., Gu, J., Lin, Z., Lai, B., Huang, L., Feng, J., Liu, B., Zhou, Y."Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor‑treated patients with non‑small cell lung cancer exhibiting bone metastasis". Oncology Letters 18.5 (2019): 5437-5447.
Chicago
Cui, X., Li, S., Gu, J., Lin, Z., Lai, B., Huang, L., Feng, J., Liu, B., Zhou, Y."Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor‑treated patients with non‑small cell lung cancer exhibiting bone metastasis". Oncology Letters 18, no. 5 (2019): 5437-5447. https://doi.org/10.3892/ol.2019.10870